What is Abrocitinib?
Abrocitinib is a Janus kinase 1 (JAK1) selective inhibitor used for the treatment of moderate-to-severe atopic dermatitis [1]. It works by inhibiting JAK1, which plays a role in the signaling pathways that contribute to inflammation and immune responses in the skin [1].
Where can I find Abrocitinib's chemical information?
Information on abrocitinib, including its chemical properties and structure, can be found on PubChem. PubChem is a public database that provides a vast collection of chemical molecules and their associated information [2].
What is Abrocitinib's patent status?
The patent landscape for abrocitinib and its related formulations is dynamic. Companies often seek patent protection for new drug substances, methods of use, and manufacturing processes. These patents can affect market exclusivity and the introduction of generic versions. For detailed patent information, including expiration dates and any ongoing litigation, resources like DrugPatentWatch.com can be consulted [3].
When does Abrocitinib's market exclusivity end?
The duration of market exclusivity for abrocitinib is determined by patent protections and any regulatory exclusivities granted. DrugPatentWatch.com tracks these expirations, which are crucial for understanding when generic or biosimilar competition might emerge [3].
How does Abrocitinib work?
Abrocitinib targets and inhibits JAK1, a key enzyme involved in the inflammatory cascade of atopic dermatitis [1]. By blocking JAK1, the drug reduces the production of cytokines that cause itching and inflammation in the skin [1].
What are the clinical uses of Abrocitinib?
Abrocitinib is approved for the treatment of adults and adolescents with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical therapies or when those therapies are not advisable [1].
What are the risks associated with Abrocitinib?
Potential risks associated with abrocitinib include serious infections, thrombosis (blood clots), major adverse cardiovascular events, and malignancy [1]. Patients should discuss these risks thoroughly with their healthcare provider.
How does Abrocitinib compare to other atopic dermatitis treatments?
Abrocitinib is part of a class of targeted therapies for atopic dermatitis, including other JAK inhibitors and biologic agents. Its efficacy and safety profile are evaluated against existing treatments to determine its place in therapy.
Who develops and markets Abrocitinib?
Pfizer Inc. developed and markets abrocitinib, which is sold under the brand name Cibinqo [4].
Sources:
1. https://www.cibinqohcp.com/atopic-dermatitis/mechanism-of-action
2. https://pubchem.ncbi.nlm.nih.gov/compound/Abrocitinib
3. https://drugpatentwatch.com/
4. https://www.pfizer.com/products/product-detail/cibinqo